Table 1.
Natural MAO inhibitors along with targeted disorders utilized molecular docking.
| Sr. No. | Enzyme | Inhibitors | Targeted Disease | Software Used | References |
|---|---|---|---|---|---|
| 1. | MAO-A | Eugenol and derivatives | Antidepressant | AutoDock 3.0 | Tao et al., 2005 [19] |
| 2. | MAO-B | 8-(3-Chlorostrylyl)caffeine | Neuroprotective | AutoDock 3.0.5 | Toprakci et al., 2005 [20] |
| 3. | MAO-A and MAO-B | Fucoxanthin | Parkinson’s disease | Autodock 4.0 | Jung et al., 2015 [21] |
| 4. | MAO-A and MAO-B | Eckol and dieckol | Parkinson’s disease | Autodock | Jung et al., 2017 [22] |
| 5. | MAO-A | Decursin Wogonin |
Neuroprotective | Autodock 4.2 | Lee et al., 2017 [23] |
| 6. | MAO-B | Homoisoflavonoid Mannich base derivatives | Alzheimer’s disease | Discovery Studio 2.5 | Li et al., 2017 [24] |
| 7. | MAO-A and MAO-B | Thioxanthone | Alzheimer’s disease | Discovery Studio 2.5 | Luo et al., 2017 [25] |
| 8. | MAO-A and MAO-B | Flavone Derivatives | Neurodegenerative disorders | Schrodinger | Jia et al., 2017 [26] |